Pliant Therapeutics Files 8-K
Ticker: PLRX · Form: 8-K · Filed: Jul 15, 2024 · CIK: 1746473
| Field | Detail |
|---|---|
| Company | Pliant Therapeutics, Inc. (PLRX) |
| Form Type | 8-K |
| Filed Date | Jul 15, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC filing, corporate disclosure
TL;DR
Pliant Therapeutics filed a routine 8-K. No major news, just standard corporate reporting.
AI Summary
Pliant Therapeutics, Inc. filed an 8-K on July 15, 2024, to report other events and financial statements. The filing does not contain specific details about new events or financial figures but serves as a standard corporate disclosure.
Why It Matters
This filing indicates Pliant Therapeutics is making a required disclosure to the SEC, which is standard practice for public companies.
Risk Assessment
Risk Level: low — This is a routine filing with no new material information or significant financial events disclosed.
Key Players & Entities
- PLIANT THERAPEUTICS, INC. (company) — Registrant
- July 15, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 331 Oyster Point Blvd, South San Francisco, CA 94080 (address) — Principal Executive Offices
FAQ
What is the purpose of this 8-K filing by Pliant Therapeutics?
The purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of July 15, 2024.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on July 15, 2024.
What is Pliant Therapeutics' principal executive office address?
Pliant Therapeutics' principal executive office is located at 331 Oyster Point Blvd, South San Francisco, CA 94080.
In which state is Pliant Therapeutics incorporated?
Pliant Therapeutics is incorporated in Delaware.
What is Pliant Therapeutics' telephone number?
Pliant Therapeutics' telephone number is (650) 481-6770.
Filing Stats: 559 words · 2 min read · ~2 pages · Grade level 12.1 · Accepted 2024-07-15 11:54:00
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share PLRX The Nasdaq Stock Mar
Filing Documents
- d829862d8k.htm (8-K) — 26KB
- d829862dex991.htm (EX-99.1) — 24KB
- g829862g0715103449331.jpg (GRAPHIC) — 2KB
- g829862g0715103449722.jpg (GRAPHIC) — 7KB
- g829862g0715103450012.jpg (GRAPHIC) — 10KB
- 0001193125-24-178937.txt ( ) — 230KB
- plrx-20240715.xsd (EX-101.SCH) — 3KB
- plrx-20240715_def.xml (EX-101.DEF) — 13KB
- plrx-20240715_lab.xml (EX-101.LAB) — 21KB
- plrx-20240715_pre.xml (EX-101.PRE) — 13KB
- d829862d8k_htm.xml (XML) — 5KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated July 15, 2024, titled "Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple Measures." 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PLIANT THERAPEUTICS, INC. Date: July 15, 2024 By: /s/ Keith Cummings Keith Cummings, M.D., MBA Chief Financial Officer